Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer
January 17th 2024The panel closes their discussion by highlighting challenges in the treatment of cervical cancer, emphasizing the need for more focus on clinical trials and therapies, as well as addressing disparities in cancer care, particularly for patients of color.
Read More
Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer
January 10th 2024Bradley Monk, MD, shares the promising potential of anti-HER2 therapy in cervical cancer and discusses encouraging results from recent trials, emphasizing the importance of testing for HER2 and considering anti-HER2 antibody drug conjugates as a treatment option.
Read More
Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs
January 3rd 2024Experts detail the management of ocular toxicity associated with tisotumab vedotin in patients with cervical cancer, emphasizing the need for eye care professionals and a team approach, along with addressing peripheral neuropathy.
Read More
Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
January 3rd 2024Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer and at least one prior line of therapy, and the management of toxicities such as neuropathy and pneumonitis.
Read More
Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer
December 27th 2023Leslie M. Randall, MD, reviews updates to the NCCN guidelines for cervical cancer, including the use of pembrolizumab in the second and third-line settings, the results of the KEYNOTE-826 trial, and the potential role of induction chemotherapy with weekly carboplatin and paclitaxel in the treatment of locally advanced cervical cancer.
Read More
Staging and Biomarker Testing For Patients With Cervical Cancer
December 27th 2023David M. O’Malley, MD, discusses cervical cancer epidemiology, risk factors, and diagnosis, highlighting the importance of HPV vaccinations, regular PAP smears, and the use of various biomarkers for treatment decision making.
Read More
Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer
December 20th 2023Experts are enthusiastic about the potential of antibody drug conjugates to de-escalate therapy and reduce toxicity in advanced and recurrent endometrial cancer treatment, with a focus on the importance of diversity plans in clinical trials to ensure broader applicability.
Read More
Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer
December 13th 2023Key opinion leaders share excitement about antibody-drug conjugates targeting HER2 in advanced or recurrent endometrial cancer, and debate optimal HER2 testing methods, with some preferring gastric cancer scoring criteria over breast cancer criteria.
Read More
Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer
December 13th 2023The panel reviews results from the ATTEND and DUO-E trials in advanced endometrial cancer, suggesting pembrolizumab remains the standard for the dMMR patient subset while combinations with PARP inhibitors may improve outcomes in pMMR.
Read More
The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
December 6th 2023Dr Thomas C. Krivak highlights key data from the GY018 trial investigating chemotherapy plus pembrolizumab in both dMMR and pMMR advanced endometrial cancer, confirming and extending the findings from the RUBY trial supporting pembrolizumab's approval and use in both dMMR and pMMR populations.
Read More
The Role of dMMR in the Progression of Endometrial Cancer
November 29th 2023David M. O’Malley, MD, details the definition of dMMR (mismatch repair deficiency), its prevalence in advanced endometrial cancer, and current treatment approaches for dMMR patients, with a focus on the potential for cure in recurrent/metastatic dMMR patients based on clinical trial data.
Read More
Shared Decision-Making in Advanced or Recurrent Endometrial Cancer
November 29th 2023The panel discusses factors to consider when determining best treatment options for patients with recurrent or advanced endometrial cancer, including traditional clinical trial endpoints, cost, chance for cure versus disease control, and most importantly, patient preference.
Read More
Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer
November 22nd 2023Key opinion leaders review recent updates to the NCCN guidelines for treating recurrent and advanced endometrial cancer, including biomarker testing and targeted therapies like dostarlimab and trastuzumab.
Read More